Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Takeda to Enhance Training of Executives with Global Business Capabilities
April 19, 2010
- JSIM Introduces COI Self-Reporting Requirement from April 12
April 19, 2010
- MCI Provides Tablet PCs to All MRs from Benesis
April 19, 2010
- Gefitinib Effective for EGFR-Positive NSCLC in First-Line Therapy
April 19, 2010
- GSK to Disclose Payments to Physicians Made in 2009 and Onward
April 19, 2010
- 637 Monitors Certified in 2nd JCROA Monitor Certification Test
April 19, 2010
- Takeda Initiates Overseas PIII Trial of SGN-35 for Lymphoma
April 19, 2010
- Norvasc, Lipitor Most Often Co-prescribed But in Only 4.3% of Patients
April 19, 2010
- Taiyo Can No Longer Be Family-Owned Company: President Aratani
April 19, 2010
- AnGes MG to Codevelop NF-κB Decoy with Shionogi
April 19, 2010
- Ajinomoto Pharm. to Enter Southeast Asian Market
April 19, 2010
- DB on Medicinal Plants Posted on NIBIO Website
April 19, 2010
- HPs Have Stronger Resistance to Generics than GPs
April 19, 2010
- Valsartan Delays Progression to Type 2 Diabetes in CV Patients with IGT
April 19, 2010
- Daiichi Sankyo Aims at 2nd Place in ARB Market in FY2012
April 19, 2010
- Korosho to Prepare New GLs for BE Testing for Generics
April 19, 2010
- Sutent Extends OS in Japanese mRCC Patients in PII
April 19, 2010
- Mochida to Boost Sales to ¥89.0 Bil. in FY2012
April 19, 2010
- Dispensing Pharmacies' Total Sales Will Continue to Decrease: JPA's Mr Iwatsuki
April 19, 2010
- Avastin + Standard Chemotherapy Significantly Extend PFS in NSCLC
April 19, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…